Registry-listed formulations

omburtamab I-131 · mesh:C000633765

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

4 source entries across 4 studies. This list may not include all unresolved or historical entries.

  • 131 I-omburtamabRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Omburtamab I-131Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • 131I-OmburtamabRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • 131I-omburtamabRegistry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Active Trials
2(50%)

Phase Distribution

Phase 2
2
50%
Phase 1
1
25%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Terminated(1)
Other(1)

Detailed Status

Active, not recruiting2
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 11 (33.3%)
Phase 22 (66.7%)

Trials by Status

active_not_recruiting250%
unknown125%
withdrawn125%

Recent Activity

2 active trials
Showing 4 of 4
active_not_recruitingphase_2

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

NCT04743661
active_not_recruitingphase_2

A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum

NCT04022213
unknown

131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults

NCT05064306
withdrawnphase_1

131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma

NCT05063357

Clinical Trials (4)

Showing 4 of 4 trials
NCT04743661Phase 2

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

Active Not Recruiting
NCT04022213Phase 2

A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum

Active Not Recruiting
NCT05064306

131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults

Unknown
NCT05063357Phase 1

131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma

Withdrawn

All 4 trials loaded

Drug Details

Intervention Type
Drug
Total Trials
4